Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a corporate governance event dated July 12, 2024. The Company is a biotechnology firm incorporated in Delaware with its principal executive offices in San Diego, California. Its common stock trades on The Nasdaq Capital Market under the symbol "BNGO."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance notice.
Material Changes
The material event reported is the receipt of a notice from The Nasdaq Stock Market LLC regarding the Company's failure to meet the Minimum Bid Price Requirement. Specifically, the closing bid price of the Company's common stock was below $1.00 per share for 30 consecutive trading days preceding July 12, 2024.
Outlook, Risks, and Contingencies
- Compliance Timeline: The Company has an initial 180 calendar days from the date of the notice to regain compliance. Compliance is achieved if the closing bid price is at least $1.00 for a minimum of 10 consecutive business days.
- Extension Possibility: If the Company fails to comply within the initial 180 days, it may be eligible for an additional 180-day period if it meets the market value of publicly held shares requirement and all other initial listing standards (excluding the bid price).
- Delisting Risk: If the Company fails to regain compliance within the applicable compliance period(s), its common stock will be subject to delisting.
- Management Action: The Company intends to monitor the stock price and may consider implementing available options to regain compliance. The filing states the notice has no immediate effect on the listing status.
Investor Verification Checklist
- Verify the current closing bid price of BNGO stock relative to the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive business days to determine if the initial compliance period is satisfied.
- Review the Company's market value of publicly held shares to assess eligibility for a potential second 180-day compliance period.
- Watch for future announcements regarding specific actions (e.g., reverse stock split) the Company may take to address the deficiency.